Green Cross Holdings Valuation

Q: What is the Fair Price of A005250 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

A005250 (₩14250) is trading above our estimate of [[fair value]] (₩5441.51)

Is A005250 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A005250 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A005250 (₩14250) is trading above our estimate of fair value (₩5441.51)

Significantly Below Fair Value: A005250 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A005250?

Key metric: As A005250 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A005250. This is calculated by dividing A005250's market cap by their current revenue.
What is A005250's PS Ratio?
PS Ratio	0.3x
Sales	₩2.11t
Market Cap	₩648.96b

A005250 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.3x
Enterprise Value/EBITDA	36.7x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does A005250's PS Ratio compare to its peers?

The above table shows the PS ratio for A005250 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	5.1x
A115450 HLB TherapeuticsLtd	13.1x	n/a	₩789.3b
A064550 Bioneer	1.7x	23.5%	₩515.9b
A086900 Medy-Tox	3.6x	12.5%	₩888.5b
A144510 GC Cell	2.2x	n/a	₩396.7b
A005250 Green Cross Holdings	0.3x	n/a	₩649.0b

Price-To-Sales vs Peers: A005250 is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (5.1x).

Price to Sales Ratio vs Industry

How does A005250's PS Ratio compare vs other companies in the KR Biotechs Industry?

27 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	8.7x	33.7%
A005250 Green Cross Holdings	0.3x	n/a	US$464.65m
A006280 GC Biopharma	0.9x	8.8%	US$1.08b
A096530 Seegene	2.5x	15.7%	US$721.30m

27 Companies		Estimated Growth	Market Cap
Industry Avg.	8.7x	65.5%
A005250 Green Cross Holdings	0.3x	n/a	US$464.65m

No more companies

Price-To-Sales vs Industry: A005250 is good value based on its Price-To-Sales Ratio (0.3x) compared to the KR Biotechs industry average (8.7x).

Price to Sales Ratio vs Fair Ratio

What is A005250's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A005250 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.3x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate A005250's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Hugel

₩3.0t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩282,000.00

6.8%

76.9%

J2KBIO

₩52.9b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,210.00

-5.0%

n/a

Medy-Tox

₩883.1b

Operates as a biopharmaceutical company in South Korea.

A086900

₩132,000.00

3.4%

-38.6%